Medicus Pharma hires Deloitte to find out-licensing partner for D-MNA (BCC)

Medicus Pharma Ltd.

Deloitte appointed exclusive lead financial adviser for out-licensing D-MNA for basal cell carcinoma.
Company will pay Deloitte retainer plus contingent success fee if a transaction closes.
Engagement letter signed July 29, 2025; no partner identified yet.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.